ALFA Filings
Every announcement, straight from the exchange
Every Sun Pharmaceutical Industries business update announcement on NSE and BSE, newest first, each with its own page.
Time
4 announcements
Sun Pharma's drug UNLOXCYT received Category 2A preferred designation in updated NCCN guidelines for treating locally advanced cutaneous squamous cell carcinoma.
Sun Pharma reported positive two-year clinical data for its LEQSELVI alopecia areata treatment, presented at the 2026 EADV Congress, highlighting sustained safety and efficacy.
Sun Pharma attended a White House signing ceremony, committing to Most Favored Nation pricing for U.S. Medicaid programs and future innovative medicine launches.
Sun Pharma's partner, Philogen, has resubmitted the Marketing Authorization Application for Nidlegy to the European Medicines Agency for the treatment of melanoma.